Zum Hauptinhalt springen

Buprenorphin

08. September 2019 | Buprenorphin

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jama…

08. September 2019 | Buprenorphin

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution Soyka, M. & Pogarell, O. Nervenarzt (2019) 90: 932. doi.org/10.1007/s00115-019-0783-6 Abstract https://link.springer.com/article/10.1007%2Fs00115-019-0…

08. September 2019 | Buprenorphin

Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].

Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet]. Edge R, Butcher R. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2…

05. September 2019 | Buprenorphin

Auf der Packungsrückseite: Falsche Wirkstoffgehaltsangabe bei Subutex

Auf der Packungsrückseite: Falsche Wirkstoffgehaltsangabe bei Subutex Die Firma Indivior ruft eine Charge Subutex 8mg Sublingualtabletten 28 Stück zurück. Der Grund: Auf der Rückseite der Packung ist der falsche Wirkstoffgehalt aufgedruckt. (Deutsc…

02. September 2019 | Buprenorphin

Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.

Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment. Withey SL, Spealman RD, Bergman J, Paronis CA. J Pharmacol Exp Ther. 2019 Aug 14. pii: jpet.119.259010. doi: 10.1124/jpet.119.259010 http://jpet.aspetj…

18. August 2019 | Buprenorphin

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine .

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine . Strang J, Knight A, Baillie S, Reed K, Bogdanowicz K, Bell J. Int J Clin Pharmacol Ther. 2018 Feb;56(2):81-85. doi…

18. August 2019 | Buprenorphin

SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS)

SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS) Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioidantagonist) Initial REMS approval: 08/2010, Most recent modification: 04/…

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten